Synthetic Lethal Approaches to Target Cancers with Loss of PTEN Function

Overview

Journal Genes Dis

Date 2023 Aug 3

PMID 37533462

Authors

Ayse Ertay

Rob M Ewing

Yihua Wang

Affiliations

Soon will be listed here.

Abstract

() is a tumour suppressor gene and has a role in inhibiting the oncogenic AKT signalling pathway by dephosphorylating phosphatidylinositol 3,4,5-triphosphate (PIP) into phosphatidylinositol 4,5-bisphosphate (PIP). The function of PTEN is regulated by different mechanisms and inactive PTEN results in aggressive tumour phenotype and tumorigenesis. Identifying targeted therapies for inactive tumour suppressor genes such as has been challenging as it is difficult to restore the tumour suppressor functions. Therefore, focusing on the downstream signalling pathways to discover a targeted therapy for inactive tumour suppressor genes has highlighted the importance of synthetic lethality studies. This review focuses on the potential synthetic lethality genes discovered in PTEN-inactive cancer types. These discovered genes could be potential targeted therapies for PTEN-inactive cancer types and may improve the treatment response rates for aggressive types of cancer.

Citing Articles

Identifying high-risk candidates for prolonging progression-free survival in primary gastric carcinoma subject to "double invasion": an analytical approach utilizing lasso-cox regression.

Wang L, Chang Y, Ma J, Qu W, Li Y BMC Cancer. 2025; 25(1):381.

PMID: 40022037 PMC: 11871700. DOI: 10.1186/s12885-025-13810-z.

The interplay of PTEN and AKT nexus in breast cancer: a molecular perspective.

Kamal A, Awan A, Rabbani M, Sheikh H, Tayyab M, Firyal S Mol Biol Rep. 2024; 51(1):345.

PMID: 38400870 DOI: 10.1007/s11033-024-09223-z.

PTEN-restoration abrogates brain colonisation and perivascular niche invasion by melanoma cells.

Wang S, Riedstra C, Zhang Y, Anandh S, Dudley A Br J Cancer. 2023; 130(4):555-567.

PMID: 38148377 PMC: 10876963. DOI: 10.1038/s41416-023-02530-5.

References

Stambolic V, Suzuki A, de la Pompa J, Brothers G, Mirtsos C, Sasaki T . Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN. Cell. 1998; 95(1):29-39. DOI: 10.1016/s0092-8674(00)81780-8. View

Maehama T, Dixon J . The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. J Biol Chem. 1998; 273(22):13375-8. DOI: 10.1074/jbc.273.22.13375. View

Al-Khouri A, Ma Y, Togo S, Williams S, Mustelin T . Cooperative phosphorylation of the tumor suppressor phosphatase and tensin homologue (PTEN) by casein kinases and glycogen synthase kinase 3beta. J Biol Chem. 2005; 280(42):35195-202. DOI: 10.1074/jbc.M503045200. View

Benitez J, Ma J, DAntonio M, Boyer A, Camargo M, Zanca C . PTEN regulates glioblastoma oncogenesis through chromatin-associated complexes of DAXX and histone H3.3. Nat Commun. 2017; 8:15223. PMC: 5437297. DOI: 10.1038/ncomms15223. View

Yin Y, Shen W . PTEN: a new guardian of the genome. Oncogene. 2008; 27(41):5443-53. DOI: 10.1038/onc.2008.241. View

Morani F, Phadngam S, Follo C, Titone R, Aimaretti G, Galetto A . PTEN regulates plasma membrane expression of glucose transporter 1 and glucose uptake in thyroid cancer cells. J Mol Endocrinol. 2014; 53(2):247-58. DOI: 10.1530/JME-14-0118. View

Lee J, Kang M, Jang S, Qian T, Kim H, Kim C . Id-1 activates Akt-mediated Wnt signaling and p27(Kip1) phosphorylation through PTEN inhibition. Oncogene. 2008; 28(6):824-31. DOI: 10.1038/onc.2008.451. View

Walker S, Leslie N, Perera N, Batty I, Downes C . The tumour-suppressor function of PTEN requires an N-terminal lipid-binding motif. Biochem J. 2004; 379(Pt 2):301-7. PMC: 1224073. DOI: 10.1042/BJ20031839. View

Nakamura N, Ramaswamy S, Vazquez F, Signoretti S, Loda M, Sellers W . Forkhead transcription factors are critical effectors of cell death and cell cycle arrest downstream of PTEN. Mol Cell Biol. 2000; 20(23):8969-82. PMC: 86551. DOI: 10.1128/MCB.20.23.8969-8982.2000. View

10.

Ciuffreda L, Di Sanza C, Cesta Incani U, Eramo A, Desideri M, Biagioni F . The mitogen-activated protein kinase (MAPK) cascade controls phosphatase and tensin homolog (PTEN) expression through multiple mechanisms. J Mol Med (Berl). 2012; 90(6):667-79. DOI: 10.1007/s00109-011-0844-1. View

11.

Sun H, Lesche R, Li D, Liliental J, Zhang H, Gao J . PTEN modulates cell cycle progression and cell survival by regulating phosphatidylinositol 3,4,5,-trisphosphate and Akt/protein kinase B signaling pathway. Proc Natl Acad Sci U S A. 1999; 96(11):6199-204. PMC: 26859. DOI: 10.1073/pnas.96.11.6199. View

12.

Sansal I, Sellers W . The biology and clinical relevance of the PTEN tumor suppressor pathway. J Clin Oncol. 2004; 22(14):2954-63. DOI: 10.1200/JCO.2004.02.141. View

13.

Georgescu M, Kirsch K, Akagi T, Shishido T, Hanafusa H . The tumor-suppressor activity of PTEN is regulated by its carboxyl-terminal region. Proc Natl Acad Sci U S A. 1999; 96(18):10182-7. PMC: 17863. DOI: 10.1073/pnas.96.18.10182. View

14.

Du C, Qi Y, Zhang Y, Wang Y, Zhao X, Min H . Epidermal Growth Factor Receptor-Targeting Peptide Nanoparticles Simultaneously Deliver Gemcitabine and Olaparib To Treat Pancreatic Cancer with Breast Cancer 2 ( BRCA2) Mutation. ACS Nano. 2018; 12(11):10785-10796. DOI: 10.1021/acsnano.8b01573. View

15.

Hartwell L, Szankasi P, Roberts C, Murray A, Friend S . Integrating genetic approaches into the discovery of anticancer drugs. Science. 1997; 278(5340):1064-8. DOI: 10.1126/science.278.5340.1064. View

16.

Brough R, Frankum J, Sims D, Mackay A, Mendes-Pereira A, Bajrami I . Functional viability profiles of breast cancer. Cancer Discov. 2011; 1(3):260-73. PMC: 3188379. DOI: 10.1158/2159-8290.CD-11-0107. View

17.

Liliental J, Moon S, Lesche R, Mamillapalli R, Li D, Zheng Y . Genetic deletion of the Pten tumor suppressor gene promotes cell motility by activation of Rac1 and Cdc42 GTPases. Curr Biol. 2001; 10(7):401-4. DOI: 10.1016/s0960-9822(00)00417-6. View

18.

Ebeid K, Meng X, Thiel K, Do A, Geary S, Morris A . Synthetically lethal nanoparticles for treatment of endometrial cancer. Nat Nanotechnol. 2017; 13(1):72-81. PMC: 5762267. DOI: 10.1038/s41565-017-0009-7. View

19.

Chalhoub N, Baker S . PTEN and the PI3-kinase pathway in cancer. Annu Rev Pathol. 2008; 4:127-50. PMC: 2710138. DOI: 10.1146/annurev.pathol.4.110807.092311. View

20.

Wen S, Stolarov J, Myers M, Su J, Wigler M, Tonks N . PTEN controls tumor-induced angiogenesis. Proc Natl Acad Sci U S A. 2001; 98(8):4622-7. PMC: 31884. DOI: 10.1073/pnas.081063798. View